Outstanding Med-Tech Buying Opportunities

Richard Hemming


This is a sector that offers you massive bang for your buck, albeit obviously at greater risk. Under the Radar’s average return on the 13 stocks we cover in health and medical technology has been 112%.

In tomorrow’s issue we discuss how we pick the stocks, then we start running through some outstanding med-tech opportunities.

There are several stocks that are running hard at the moment. One of those is definitely Medical Developments International (MVP), which at the moment can do no wrong. The UK authorities authorised MVP’s "Green Whistle" Penthrox pain relief device for use in every ambulance service in the UK, and the company has also achieved clearance in Mexico for use in moderate to severe pain trauma cases and surgical procedures requiring analgesia.The surgical application is relatively new to MVP.

We first bought the stock at $1.18 back in May 2014 when it had a market cap of under $70m. Fast-forward three and a half years and the company has issued no more shares and its stock price is $6.40, giving it a valuation of $378m.

This company has low regulatory risk, it’s got proven products, it’s producing positive cash flow, and it’s covered in tomorrow’s issue. Is it time to BUY/SELL OR HOLD?

We’ve had some good feedback from last week’s “Battery Powered” Report on lithium stocks. This could be because the ones we rated spec buy, Pilbara Minerals (PLS), Mineral Resources (MIN) and Kidman Resources (KDR) are up an average of 11% at the time of writing. Who knows, that could be any figure by the time you read this. In tomorrow's report we cover a nickel miner whose stock is climbing quickly because it's also a beneficiary of battery power. It’s worth checking out if you believe in that theme.



About the Author

Richard Hemming

Richard Hemming (r.hemming@undertheradarreport.com.au) is an independent analyst who edits www.undertheradarreport.com.au, which provides investment opportunities in Small Caps that you won’t get anywhere else.

Under the Radar Report is licensed to give general financial advice only (AFSL: 409518). The author does not own shares in any of the stocks mentioned.

Did you miss?

As Seen In